Orexo AB (STO: ORX) (OTCQX: ORXOY), a Sweden-based pharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for review of OX124.
OX124 is a nasal rescue medication for opioid overdose containing a high dose of naloxone and is the first product based on Orexo´s drug delivery platform, amorphOX. The Prescription Drug User Fee Act (PDUFA) date is set to 15 July 2024, but recent review processes in the category indicate a risk of some delay.
OX124 is a potent medication and, in combination with rapid absorption and high bioavailability, this makes it capable of reversing an overdose or sustaining consciousness in a patient who has taken synthetic opioids.
It is an innovative powder-based technology that improves stability and reduces sensitivity related to temperature changes in addition to rapid absorption and high bioavailability.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment